Clinical Trial Update: A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing MEHD7945A versus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• MEHD7945A (MEHD7945A)

Snippet

Sponsor: Genentech, Inc. | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED